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Ge, Ri-Li, S. Witkowski, Y. Zhang, C. Alfrey, M. Sivieri, T. Karlsen, G. K. Resaland, M. Harber, J. StrayGundersen, and B. D. Levine. Determinants of erythropoietin release in response to short-term hypobaric hypoxia.
J Appl Physiol 92: 2361–2367, 2002. First published November 30, 2001; 10.1152/japplphysiol.00684.2001.—We measured blood erythropoietin (EPO) concentration, arterial O2
saturation (SaO2), and urine PO2 in 48 subjects (32 men and
16 women) at sea level and after 6 and 24 h at simulated
altitudes of 1,780, 2,085, 2,454, and 2,800 m. Renal blood flow
(Doppler) and Hb were determined at sea level and after 6 h
at each altitude (n ⫽ 24) to calculate renal O2 delivery. EPO
increased significantly after 6 h at all altitudes and continued to increase after 24 h at 2,454 and 2,800 m, although not
at 1,780 or 2,085 m. The increase in EPO varied markedly
among individuals, ranging from ⫺41 to 400% after 24 h at
2,800 m. Similar to EPO, urine PO2 decreased after 6 h at all
altitudes and returned to baseline by 24 h at the two lowest
altitudes but remained decreased at the two highest altitudes. Urine PO2 was closely related to EPO via a curvilinear
relationship (r2 ⫽ 0.99), although also with prominent individual variability. Renal blood flow remained unchanged at
all altitudes. SaO2 decreased slightly after 6 h at the lowest
altitudes but decreased more prominently at the highest
altitudes. There were only modest, albeit statistically significant, relationships between EPO and SaO2 (r ⫽ 0.41, P ⬍
0.05) and no significant relationship with renal O2 delivery.
These data suggest that 1) the altitude-induced increase in
EPO is “dose” dependent: altitudes ⱖ2,100–2,500 m appear
to be a threshold for stimulating sustained EPO release in
most subjects; 2) short-term acclimatization may restore renal tissue oxygenation and restrain the rise in EPO at the
lowest altitudes; and 3) there is marked individual variability in the erythropoietic response to altitude that is only
partially explained by “upstream” physiological factors such
as those reflecting O2 delivery to EPO-producing tissues.

to high-altitude hypoxia,
they exhibit certain physiological responses, such as
the production of erythropoietin (EPO), which triggers
an increase in red cell mass and Hb concentration (7,
10, 11, 35). This hematologic acclimatization response

facilitates the restoration of normal blood O2 content
and improves tissue oxygenation, despite lowered arterial PO2 (PaO2). The concentration of EPO in blood
increases ⬃90–120 min after reduction of the inspiratory PO2 (5), rises progressively during the first 24–48
h, and then declines toward baseline over days to
weeks (1, 28).
The role of EPO in the polycythemia induced by field
and simulated (hypobaric chamber) altitude has been
studied extensively in humans (1, 28, 29) and animals
(12, 15). However, most studies were conducted at high
altitudes (⬎4,000–6,000 m) (15, 21, 28, 29). Crosssectional studies show a curvilinear relationship between PaO2 and red cell mass, with no increase until
PaO2 decreases below 70 Torr, and arterial O2 saturation (SaO2) begins to decrease prominently (35). However, whether sea level natives will experience stimulated erythropoiesis in response to lower altitudes is
unknown. This question is particularly important to
certain populations such as endurance athletes who
travel to moderate altitude for training purposes (17,
31), as well as the millions of people exposed to moderate altitude during occupational and/or recreational
activities (23).
The EPO-producing site in response to hypoxia is
primarily the kidney (20), although extrarenal sensing
mechanisms also have been postulated in experimental
animals (30). It is assumed that a change in the delivery of O2 to renal tissue is a key factor for stimulating
EPO production at altitude. However, this assumption
has not been demonstrated directly in human studies.
Renal O2 delivery is regulated not only by renal blood
flow (RBF) and arterial O2 content (CaO2), but also by
hemodynamics (such as cardiac output) and the affinity of Hb for O2 (35). Ultimately, it is the difference
between renal O2 delivery and renal O2 utilization that
determines O2 content of the kidney cells, which is not
necessarily linearly related to arterial oxyhemoglobin
saturation.
In the present study, we hypothesized that there
would be a threshold “dose” of altitude exposure that
would be required for sustained EPO release and that
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the magnitude of the response would be based on
variability in known physiological parameters. To test
this hypothesis, we measured blood EPO, urine PO2 as
an index of renal tissue PO2, RBF, and SaO2 in 48
subjects at sea level and at four levels of simulated
altitude.
METHODS

Subjects. Forty-eight young, healthy subjects (32 men and
16 women, 21 ⫾ 2.5 yr, 61.3 ⫾ 10.4 kg, 170 ⫾ 12 cm)
volunteered to take part in the study. All subjects received
written and verbal explanations of the experiment before
giving consent. The Institutional Review Boards of the University of Texas Southwestern Medical Center and Presbyterian Hospital of Dallas approved the study.
Protocol. Each week, for a total of 4 wk, the subjects spent
24 h in a decompression chamber at simulated altitudes of
1,780, 2,085, 2,454, and 2,800 m (612, 590, 564, and 538 Torr
barometric pressure, respectively) in pseudo-random and
balanced order (ultimately, order was 2,454, 2,800, 2,085,
and 1,780 m). The last altitude was fixed a priori at 1,780 m
to minimize any effect of the chamber exposures on subsequent experiments conducted in the field. For comfort, only
12 subjects were in the chamber during any 24-h exposure.
The temperature (25 ⫾ 0.5°C), humidity (28 ⫾ 1%), and CO2
concentration (0.07 ⫾ 0.02%) in the chamber were carefully
controlled.
EPO concentration. EPO concentration was measured at
sea level (before decompression) and after 6 and 24 h at each
simulated altitude. For logistical reasons, in half of the subjects, EPO was measured in plasma by radioimmunoassy
(Ramco, Houston, TX), and in the other half, it was determined in serum with an enzyme-linked immunosorbent assay kit (Human EPO Quantikine IVD, catalog no. DEP00,
R & D Systems) (2). On one set of 72 samples, EPO concentration was assayed in plasma and serum with these respective kits to determine the relationship between the two methods. The plasma and serum EPO values were tightly
correlated with a regression coefficient of 0.96, a slope of 1.0,
and an intercept of 2.7 (i.e., plasma values were 2.7 mU/ml
higher than serum values in a systematic fashion but varied
together in a 1:1 relationship). To minimize any influence of
this difference between the two methods for calculating percent changes in EPO, all serum values were adjusted by this
offset (2.7) to make them equivalent to the plasma measurements. Hb was measured by a CO-oximeter (Instrumentation
Laboratories).
Urinary PO2. Urine samples were collected anaerobically
at sea level and after 6 and 24 h at each simulated altitude
with the use of the following procedure. 1) Each subject
voided to empty his/her bladder. 2) After the first void, each
subject drank 500 ml of a hypotonic sports drink (Gatorade).
3) About 30 min after drinking the Gatorade, subjects voided
through an external catheter to a vinyl bag, with care taken
to avoid exposure to air. For men, this was achieved with a
standard “condom”-style catheter (C. R. Bard). For women,
an external collection device developed for use in space was
employed (Medpoint, Chicago, IL). This procedure produced
a urine flow rate of 5–10 ml/min. 4) Immediately after collection, the urine samples were drawn into a 2-ml syringe
and placed immediately on ice. The urine PO2 was analyzed
with a blood-gas analyzer (Instrumentation Laboratories).
RBF. RBF was measured in 24 subjects (16 men and 8
women) at sea level and after 6 h of each altitude exposure by
using Doppler ultrasonography (22, 36). A color Doppler
ultrasound scanner (model HDI 5000, Advanced Technology
J Appl Physiol • VOL

Laboratory, Bothel, WA) was used for examination. After the
flow in internal vessels was identified with color Doppler
ultrasonography, a sample volume was positioned in the
renal artery or its first branch. The sample volume was
placed in exactly the same position for each determination
(based on a scout image during the first measurement), and
the Doppler velocity was corrected for the angle of insonation. Volumetric flow was calculated by multiplying the
area of the insonated blood vessel by the time-averaged mean
velocity over at least three consecutive beats. Renal O2 delivery was calculated from the product of RBF and CaO2
[CaO2 ⫽ Hb (g/dl) ⫻ SaO2 (%) ⫻ 1.36 (ml O2/g)].
SaO2. SaO2 was estimated by pulse oximetry (model 3700,
Ohmeda) at sea level and after 6 and 24 h at each simulated
altitude.
Statistical analysis. Values are means ⫾ SE. Sea level
values (baseline) were taken from the mean values of four
measurements, which were made immediately before each
simulated altitude exposure. The EPO, urine PO2, and SaO2
data at different altitudes and times were analyzed by means
of a two-way (repeated-measure) analysis of variance. The
Newman-Keuls post hoc test was used for multiple comparisons between variables. Linear regression analysis and correlation coefficients were used to assess the relationships
between variables. Comparison and correlation were considered significant when P ⬍ 0.05.
RESULTS

EPO. EPO was 14.3 ⫾ 0.8 mU/ml at sea level; it
increased significantly after 6 h at all four simulated
altitudes and then declined slightly after 24 h at 1,780
and 2,085 m. In contrast to the two lowest altitudes,
mean EPO concentration continued to increase significantly after 24 h at 2,454 and 2,800 m (Fig. 1A). There
was marked individual variability in EPO release at all
altitudes (Fig. 2) but generally consistent responses
among individuals (i.e., those individuals with the
greatest responses to the lowest altitudes had the
greatest responses to the highest altitudes). For example, the coefficient of variation (standard deviation/
mean) for the percent change from baseline after 24 h
at 2,800 m was 0.83.
Urine PO2. Changes in urine PO2 are shown in Fig.
1C. The mean value of urine PO2 at sea level was 84.7 ⫾
1.7 Torr; similar to the pattern for EPO, it decreased
after 6 h at all altitudes and returned rapidly to near
baseline by 24 h at 1,780 and 2,085 m but remained
lower at 2,454 and 2,800 m. There was a highly significant curvilinear (2nd-order regression) relationship
between the mean values for urine PO2 and EPO by
24 h at all four simulated altitudes (r2 ⫽ 0.992; Fig. 3).
When examined on an individual basis, the median r2
for this relationship was 0.87 (range 0.11–1.00).
SaO2. SaO2 at sea level was 98.1 ⫾ 0.4%, decreased
slightly but significantly after 6 h at 1,780 and 2,085 m
(1.1 and 1.6%, respectively), and decreased to a greater
extent at 2,454 and 2,800 m (4.8 and 5.4%, respectively). It returned to baseline by 24 h at the two lowest
altitudes but remained significantly reduced at the two
highest altitudes (Fig. 1B). The magnitude of desaturation from sea level after 24 h at each simulated
altitude (⌬SaO2) was correlated to the degree of the
increase in EPO (⌬EPO) rise (r2 ⫽ 0.17, P ⬍ 0.05; Fig.
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Fig. 1. Changes in erythropoietin (EPO), arterial
oxyhemoglobin saturation (SaO2), and PO2 in
urine from sea level (baseline, BL) and after 6
and 24 h at simulated altitudes of 1,780, 2,085,
2,454, and 2,800 m in 48 subjects. Values are
means ⫾ SE. Because data for 1,780 and 2,085 m
and 2,454 and 2,800 m behave similarly, double
symbols for significance mean that both groups
achieved the same level of significance: ** P ⬍
0.05 compared with baseline for 6 and 24 h;
##
P ⬍ 0.05 compared with the lower altitudes. In
B and C, double symbols represent the same
comparison as in A; single symbols represent
comparisons that are valid only for that specific
altitude and are placed directly over the data
symbol: * P ⬍ 0.05 compared with the previous
time point; # P ⬍ 0.05 compared with the lower
altitude.

4). Thus the change in SaO2 accounted for ⬍20% of the
variability in EPO concentration.
RBF. RBF values are shown in Table 1. There was no
significant difference in RBF at 6 h compared with sea
level values at all simulated altitudes. When SaO2 and
Hb were factored in (i.e., renal O2 delivery), there was
no significant influence of renal O2 delivery on EPO
release at these moderate altitudes.
DISCUSSION

The principal findings of this study include the observation that short-term, sustained EPO production
occurs at moderate altitude once a threshold of 2,100–
2,500 m is crossed. Below this altitude, changes in EPO
are modest and not sustained after 24 h of exposure in
the majority of individuals. Moreover, EPO production
at altitude is marked by substantial interindividual
variability, governed by “upstream” factors related to
renal parenchymal PO2, as well as other undetermined
mechanisms, presumably related to transcriptional
regulation of EPO by renal tissue hypoxia.

Optimal threshold altitude for EPO release. EPO is a
glycoprotein hormone that regulates proliferation and
differentiation of erythroid cells. Its production is
markedly enhanced by reductions in CaO2 mediated by
anemia or hypoxia (6, 20) and certain metals such as
cobalt and nickel (37). A number of physiological studies demonstrated that the concentration of EPO is
substantially increased after high-altitude exposure
and then gradually declines toward baseline within the
first few days to weeks of exposure (21, 28, 29).
However, most studies examining the erythropoietic
effect of altitude have used much higher altitudes (and,
therefore, more severe hypoxia) than reported in the
present study, generally ⬎4,000 m. In contrast, the
majority of occupational and recreational exposures
occur at more moderate altitudes, between 2,000 and
3,000 m (23). Some populations, such as endurance
athletes, routinely travel to moderate altitudes with a
goal to improve sea level performance via altitudeinduced erythrocytosis (17). However, cross-sectional
studies by Weil et al. (35) demonstrated that an eryth-

Fig. 2. Individual values for percent change in EPO
from baseline in all subjects. Note marked individual
variability that increases with increasing altitude.

J Appl Physiol • VOL
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Fig. 3. A–C: EPO-urine PO2 relationship in a
subject with a relatively minimal increase in
EPO, despite decreases in urine PO2 (A), a
subject with a brisk response (C), and a subject with an intermediate response (B). D:
blood EPO levels plotted as a function of
urine PO2 at simulated altitudes of 1,780,
2,085, 2,454, and 2,800 m. Data were obtained from the mean group value for each
altitude after 24 h (n ⫽ 48). Mean urine PO2
was significantly correlated to blood EPO levels as a 2nd-order regression (r2 ⫽ 0.992, P ⬍
0.01).

ropoietic response to hypoxia is not achieved until PaO2
decreases to ⬃65–70 Torr (corresponding to an altitude
of 2,500–3,000 m in sedentary individuals); red cell
mass and PaO2 are linearly correlated when altitudeinduced hypoxemia becomes more severe. Whether
such a threshold is present in sea level natives ascending to moderate altitude is uncertain.

Fig. 4. Magnitude of desaturation (⌬SaO2) from baseline to simulated altitude is correlated to the degree of increase in EPO (⌬EPO).
As a group, there was a modest correlation between ⌬SaO2 and ⌬EPO
by 24 h at 4 simulated altitudes (n ⫽ 192, r ⫽ 0.41, P ⬍ 0.05).
J Appl Physiol • VOL

Previous studies at moderate altitudes have consistently demonstrated an increase in EPO of a magnitude similar to that observed in the present study in
response to real or simulated altitude (normobaric or
hypobaric hypoxia) of ⬃2,500 m (2, 4, 5, 9, 14, 17). One
study (5) compared the acute (5.5 h) effect of 3,000 vs.
4,000 m in a hypobaric chamber and demonstrated a
more rapid rate of rise and a proportionately greater
increase in EPO at the higher altitude. The present
study extends these previous observations by demonstrating what appears to be a threshold, rather than a
continuous linear relationship, at lower altitudes. Specifically, the EPO levels at the two lowest altitudes
increased modestly (24–30%), peaking at 6 h after
exposure; in contrast, EPO increased more prominently (77–92%) at the two highest altitudes, with a
continued increase after 24 h at 2,500 and 2,800 m
(Fig. 1A). These observations suggest that altitudes
⬎2,100–2,500 m appear to be required for stimulating
sustained EPO release.
The mechanism of this differential response is likely
to include the greater oxyhemoglobin desaturation
that occurs as the PO2 falls to the steep portion of the
oxyhemoglobin dissociation curve. Thus the EPO levels
at all altitudes paralleled the changes in SaO2; the
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Table 1. Comparisons of various parameters at sea level and simulated altitude exposure
1,780 m

EPO, m/l
uPO2, Torr
SaO2, %
RBF, ml/min

2,085 m

2,454 m

2,800 m

SL

6h

24 h

6h

24 h

6h

24 h

6h

24 h

14.3 ⫾ 5.3
85.1 ⫾ 11
98.1 ⫾ 0.4
326 ⫾ 154

18.6 ⫾ 6.2
69.6 ⫾ 8.8
97.1 ⫾ 0.9
398 ⫾ 102

19.6 ⫾ 6.9
83.9 ⫾ 12
97.4 ⫾ 0.8

18.9 ⫾ 7.0
68.4 ⫾ 11
96.5 ⫾ 1.0
396 ⫾ 92

19.4 ⫾ 8.2
80.1 ⫾ 11
96.6 ⫾ 1.5

19.8 ⫾ 7.3
69.1 ⫾ 9.7
93.4 ⫾ 2.3
342 ⫾ 121

25.4 ⫾ 9.8
71.6 ⫾ 8.7
93.7 ⫾ 2.0

20.9 ⫾ 12.6
62.9 ⫾ 13.4
92.8 ⫾ 2.5
362 ⫾ 103

27.2 ⫾ 5.3
70.4 ⫾ 9.8
93.2 ⫾ 2.5

Values are means ⫾ SD. EPO, erythropoietin; uPO2, urine PO2, SaO2, arterial O2 saturation; RBF, renal blood flow.

magnitude of desaturation at altitude was correlated to
the degree of the increase in EPO, suggesting that
there may be an inadequate hypoxic stimulus for the
production of EPO at ⬍2,100 m. However, the strength
of this relationship was relatively weak, with a correlation coefficient, albeit statistically significant, of only
0.42. Part of this weak relationship may be explained
by the fact that the changes in SaO2, among the different altitudes and at each altitude, compared with control were very small. For example, mean SaO2 values
fell by ⬍1% at 1,780 m, which was statistically significant as a group effect but within the limits of precision
of the pulse oximeter for any individual measurement.
In this regard, it is remarkable that such clear differences in EPO levels occurred, despite relatively small
differences in SaO2. The relationship between SaO2 and
EPO, particularly at the earliest time point, may be
further complicated by the fact that the rate of EPO
production in response to altitude-induced hypoxia is
likely to be variable depending on the absolute degree
of hypoxia achieved (5).
One additional confounding factor may be that the
renovascular bed autoregulates sufficiently to maintain adequate renal O2 delivery, despite systemic hypoxia. In the present study, RBF after 6 h of exposure to
simulated high altitude was not significantly different
from RBF at sea level. Moreover, EPO levels at all
simulated altitudes were not correlated with renal O2
delivery, incorporating measures of RBF and CaO2.
These data suggest that, within the limits of our methodology to detect changes in RBF, renal O2 delivery,
by itself, is not a strong determinant of EPO production
in humans, as has been demonstrated in animal studies (25).
Urine PO2 as an estimate of renal tissue PO2. However, renal O2 delivery reflects only one side of the
equation: ultimately, renal parenchymal PO2, a function of renal O2 delivery minus renal O2 utilization,
appears to be the essential determinant of EPO production (11, 37). Thus renal vein or urine PO2 as an
estimate of renal tissue PO2 may be a better marker of
the stimulus for EPO release than SaO2 or renal O2
delivery (24). To our knowledge, this is the first study
to measure urine PO2 in humans at different altitude
exposures, although other investigators have demonstrated increases in urine PO2 during increases in PO2
mediated by hyperoxia (13, 18, 27). Moreover, graded
reductions in RBF lead to similarly graded reductions
in urinary PO2, confirming the dependence of urine PO2
on renal O2 availability (13). According to the concept
J Appl Physiol • VOL

of countercurrent gas diffusion (27), urine PO2 in the
collecting ducts is lower than the venous PO2. The
estimated renal venous PO2 at sea level is ⬃70–80 Torr
in humans (27) and 50–60 Torr in rats (24). Renal
tissue EPO and plasma EPO in rats have been correlated to renal venous PO2 during exposure to chronic
hypoxia in a curvilinear relationship similar to that
observed in humans in the present study (24).
A number of technical issues must be considered in
the interpretation of measurements of urinary PO2.
First, it should be recognized that the kidney is not
uniform in its oxygenation, with gradations of PO2 from
the outer cortex to the inner medulla (16). Moreover,
urine PO2 is sensitive to hydration state, with most (16,
26), but not all (18), studies showing an increase in
urine PO2 with increasing degrees of hydration and/or
urine flow rates. Conversely, if urine flow rates are too
low, i.e., ⬍3 ml/min, there is significant uptake of O2 in
the walls of the ureters and bladder, reducing bladder
PO2 compared with renal pelvic PO2 (27); flow rates of
ⱖ5 ml/min are necessary to ensure that urethral collections reflect the PO2 from the renal pelvis (27). Finally, a prominent water diuresis (26) or saline loading
(18) can influence the results by increasing or decreasing urine PO2, respectively. Fortunately, when hydration status is carefully controlled and urine flow rates
are neither too low nor too high, urine PO2 is very
reproducible in any given subject from day to day and
is a reasonable reflection of renal medullary oxygenation (8, 18, 26). In the present study, baseline sea level
measurements of urine PO2 were reproducible from
week to week and similar to data reported by other
investigators (8).
In our study, the urine PO2 was significantly decreased by 6 h at all altitudes and then rapidly returned to near baseline by 24 h at the two lowest
altitudes and remained significantly low at the two
highest altitudes (Fig. 1C), closely paralleling the
changes in arterial oxyhemoglobin saturation. The
threshold above and below 2,100 m that was clearly
evident in EPO and SaO2, even at the first time point (6
h), was not manifest until 24 h for the urine PO2 data.
Although we cannot determine with certainty the
mechanism for this differential response, we speculate
that the different time courses of ventilatory acclimatization, neurohumoral activation, and renal metabolic
compensation may be at least partly responsible for
this inconsistency. The very small differences among
the altitudes studied and the resultant experimental
noise may also be playing a role at this early stage,
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before the overall response becomes more complete
after a full 24 h of exposure.
We suspect, but cannot prove, that the short-term
acclimatization response (primarily ventilatory acclimatization) appears to restore renal tissue oxygenation rapidly and restrain the rise in EPO at the lowest
altitudes. For example, we did not measure ventilation
or end-tidal CO2 concentrations and thus have only
indirect evidence that ventilatory acclimatization occurred at these low altitudes. However, we can say that
although the magnitude of the hypoxia (as estimated
from SaO2) experienced at the lowest altitudes was
modest, the consistent decrease in urine PO2 and subsequent rise in EPO provide compelling evidence that
this hypoxia was physiologically significant at all altitudes and likely to stimulate peripheral chemoreceptors. Most dramatically, on average, changes in urine
PO2 were strictly proportional to EPO levels at all four
altitudes (r2 ⫽ 0.992). This strong, possibly deterministic, relationship supports the hypothesis that renal
tissue PO2 is an essential factor for determining EPO
production in humans at high altitude.
Individual variability of EPO production. Despite
this tight relationship for the mean group data, the
individual relationships between urine PO2 and EPO
were highly variable (Fig. 3). Moreover, EPO levels in
response to short-term simulated altitude exposure
demonstrated marked interindividual variability, ranging from ⫺41 to 400% after 24 h of exposure to 2,800 m
(Fig. 2). Intriguingly, the EPO response was generally
consistent among individuals; i.e., those individuals
with the greatest response to the lowest altitudes had
the greatest response to the highest altitudes. Some
insight into possible mechanisms for this variability
may be found in a recent animal study in which blood
EPO and renal tissue EPO in response to acute or
chronic hypoxic exposure were dramatically different
in two rat strains, suggesting that genetic factors may
be involved in the regulation of the EPO response (24).
In this study, the curvilinear relationship between
renal tissue PO2 and EPO, as well as a marked difference between strains in the transcription of mRNA for
EPO in response to a given renal tissue PO2, argued
strongly for transcriptional regulation of EPO synthesis at altitude and was remarkably similar to the data
found in the present study in humans.
There is increasing evidence that hypoxia-induced
physiological changes depend on intracellular O2 sensors that are present in most mammalian cells (34, 37).
A specific O2 sensor has been identified in the carotid
body (19), neuroepithelial bodies (3), and other cells
with O2 sensitivity (30, 32), although it remains unclear how the kidney responds precisely to O2 content.
EPO gene expression is regulated primarily at the level
of transcription in these O2-sensitive cells. This O2sensing system (by hypoxic exposure) triggers production of hypoxia-inducible factor-1␣ (33), a major transcription factor that binds to the human EPO gene
3⬘-flanking region and initiates transcriptional activation of the EPO gene in the hypoxic cells of the kidneys
(34). In light of these observations, we speculate that
J Appl Physiol • VOL

these transcriptional and posttranscriptional mechanisms for governing the regulation of EPO gene expression may be playing a substantial role in the observed
individual variability.
In summary, we conclude that short-term, sustained
EPO production in response to simulated altitude has
a clear threshold: altitudes ⬎2,100–2,500 m are required to stimulate a sustained increase in group EPO
concentrations over 24 h. Despite this population effect, EPO production at altitude is marked by substantial interindividual variability, with some individuals
exhibiting ⬃100% increases in EPO levels to exposures
of 1,780 m, whereas others did not increase EPO levels
in response to 2,805 m. This variability appears to be
governed by upstream factors related to renal parenchymal PO2, as well as by other undetermined mechanisms, presumably related to transcriptional regulation of EPO by renal tissue hypoxia.
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